Explore every episode of the podcast Summit Lens
| Title | Pub. Date | Duration | |
|---|---|---|---|
| When AI Enters the Exam Room | 13 sept. 2026 | 00:38:21 | |
AI can already read scans, flag high-risk patients, guide ultrasound exams, and even make some autonomous diagnostic decisions. But that raises a more important question: does a better model actually lead to better care? In this episode, we follow what happens after the algorithm gives an answer. We look at why GPT-4 did not automatically make physicians better diagnosticians, how AI cut mammography reading workload by 44%, why some clinical alerts become noise while others speed up stroke treatment, and what happens when AI moves expertise closer to the patient. We also look at one of the rare randomized trials linking an AI alert to lower mortality—and why some of the fastest-moving healthcare AI may be doing something far less glamorous: writing the clinical note. The real story of medical AI may not be whether machines can outperform doctors. It may be whether healthcare systems know what to do with what the machines find. Timestamps
| |||
| When Healthcare Becomes an Investment Thesis | 07 sept. 2026 | 00:51:02 | |
You may know your doctor. But do you know who owns the business around your doctor? Private equity usually does not show up in healthcare with a Wall Street label. It shows up more quietly, in the local practice that keeps its old name, the specialist group inside a hospital, or the clinic that suddenly feels more optimized than before. The care may look familiar. The ownership may not be. In this episode, we follow how private equity became one of the most important and least visible ownership forces in the US healthcare. The story starts with the private equity model itself: raise capital, use leverage, buy a platform, add smaller practices, centralize operations, optimize revenue, and sell on a fund timeline. Then we ask why healthcare fit that model so well. The answer is uncomfortable: fragmented providers, opaque prices, third-party payment, complex billing, recurring demand, and physicians exhausted by the business side of medicine. We follow that playbook from physician practices to emergency staffing, outpatient specialties, nursing homes, and hospital real estate. This is not a simple story about private equity being good or bad. Some practices need capital. Some physicians sell for rational reasons. Some platforms bring better technology and cleaner operations. But when care becomes an investment asset, the logic around the exam room can change: what gets scheduled, what gets billed, which services grow, how doctors practice, and what patients experience without ever seeing the ownership change. The takeaway is simple: In the US healthcare, ownership is now part of the care model. The question is no longer only, “Who is my doctor?” It is also, “Who owns the system around my doctor and what is that owner optimized to do?” Timestamps
| |||
| Why Hospitals Became the Price Setters | 30 août 2026 | 00:56:10 | |
Why can the same care cost more when the doctor, the room, and the service have not changed? In this episode, we look at how hospitals became some of the most powerful price setters in American healthcare. We start with a routine cardiology visit that suddenly costs almost three times more after the practice becomes part of a hospital system. From there, we unpack the larger structure behind that bill: hospital consolidation, must-have health systems, commercial prices, facility fees, physician practice acquisitions, and the policy fight over site-neutral payments. This is not a simple story about hospitals being good or bad. Some health systems have enormous leverage. Some rural hospitals are barely staying open. And many policy solutions come with real tradeoffs. But the central tension is clear: in healthcare, scale can create survival — and scale can create pricing power. Timestamps
| |||
| Why Having Insurance Still Feels Expensive | 19 août 2026 | 00:59:07 | |
What does it actually mean to have health insurance in America? In this episode, we look at the Affordable Care Act not as a partisan debate, but as a systems story. The ACA changed who could enter the insurance market. It made it harder for insurers to deny coverage because of pre-existing conditions, removed annual and lifetime limits, expanded Medicaid in many states, and created subsidized marketplaces for people outside employer coverage. But it did not fully change what care costs once someone gets inside the system. So the central question is not simply whether the ACA succeeded or failed. It is what kind of problem the law was built to solve, and what kind of problem it left behind. We follow that question from a kitchen table during open enrollment to pre-ACA medical underwriting, marketplace plan design, narrow networks, underinsurance, Medicaid expansion, temporary subsidies, and the deeper cost structure underneath American healthcare. Because having insurance is not always the same as being able to afford care. Timestamps
| |||
| When Washington Becomes the Drug Price Negotiator | 11 août 2026 | 00:58:39 | |
What happens when Medicare stops only paying for drugs and starts naming the price? In this episode, we look at the Inflation Reduction Act and Medicare drug price negotiation, not as a policy explainer, but as a shift in power inside the U.S. drug market. For nearly two decades, Medicare Part D relied on private plans, PBMs, formularies, and rebates to negotiate drug costs. The IRA changed that architecture. Washington is now setting prices for selected high-spend Medicare drugs, and every part of the system is adapting around that new signal. We follow the story from the pharmacy counter to the manufacturer revenue model, the Part D plan bid, the PBM rebate negotiation, and the biotech investment decision. The question is no longer only whether Medicare can negotiate a lower price. It is what happens when that price becomes part of the operating system for the US drug markets. Timestamps
| |||
| When GLP-1 Meets the Real World | 15 juin 2026 | 00:39:59 | |
GLP-1 proved the science could work. The harder test began once patients tried to get it. In this episode, we follow GLP-1 from the pharmacy counter into the real world of American healthcare: insurance coverage, compounding pharmacies, PBM formulary decisions, employer benefit design, cash pay pathways, TrumpRx, and public policy. The question is no longer only whether these drugs work. It is how the system decides who gets access when a treatment is effective, expensive, highly demanded, and potentially preventive. And for many patients, the answer depends on which door is actually open. Timestamps
| |||
| How GLP-1 Went From Biology to Blockbuster | 04 juin 2026 | 00:51:09 | |
How did a gut hormone that disappeared in seconds become one of the biggest drug classes in the world? In this episode, I walk through the story of GLP-1, from early scientific discovery and the Gila monster breakthrough to Novo Nordisk’s drug design strategy, Eli Lilly’s competitive push, and the shift that turned GLP-1 from a diabetes treatment into something much bigger. This is a story about how a hard biological problem became a pharmaceutical platform, and how that platform began to change the way medicine thinks about obesity, metabolism, and chronic disease. Timestamps
| |||
| Why Making the Drug Is Only Half the Battle | 11 mai 2026 | 00:55:08 | |
What does it actually take to turn a scientific breakthrough into a drug patients can access? In this episode, I look at the manufacturer side of the healthcare system, the part that absorbs scientific failure, funds long-shot bets, and then enters a second battle after the science succeeds. Because FDA approval is not the finish line. It is the point where a therapy enters the real commercial system: one shaped by patent clocks, launch pricing, payer resistance, formulary access, rebates, and budget pressure. This is a story about the economics of failure, the logic of blockbuster drugs, and the central tension at the heart of modern pharma: scientifically essential, politically unpopular, financially powerful, and commercially constrained at the same time. Between the lab bench and the patient sits a market that does not simply reward innovation. It prices it, filters it, delays it, and redistributes its value. Timestamps
| |||
| Who Really Controls Your Prescription? | 27 avr. 2026 | 01:08:39 | |
If your doctor writes a prescription, who actually decides whether you get it, where you fill it, and what you pay? In this episode, I unpack the hidden role of pharmacy benefit managers, or PBMs, the intermediaries that sit between drugmakers, insurers, employers, pharmacies, and patients. PBMs do not invent drugs or prescribe them, but they often control formularies, prior authorization, specialty pharmacy channels, and the financial terms that shape access. I trace how PBMs evolved from claims processors into powerful gatekeepers, explain how rebates, spread pricing, specialty pharmacy, and step therapy work, and examine the central debate: are PBMs lowering costs, or making the system more opaque while controlling who gets what medicine? From insulin and biosimilars to specialty drug markups and the latest reform pressure, this is a story about the financial architecture between the prescription pad and the patient. Timestamps
| |||
| How Private Insurers Took Over American Healthcare | 15 avr. 2026 | 00:53:39 | |
What happens when an insurance company stops acting like a payer and starts acting like infrastructure? In this episode, I explore how private insurers became some of the most powerful actors in American healthcare. Using UnitedHealth Group as a central case study, I trace the shift from passive bill payer to managed care gatekeeper to vertically integrated healthcare empire. From Medicare Advantage and self-funded employer plans to Optum, PBMs, and the Change Healthcare crisis, this is a story about how private insurers scaled, consolidated, and embedded themselves into the plumbing of the U.S. health system. Timestamps
| |||
| Why U.S. Healthcare Is So Complicated | 06 avr. 2026 | 00:52:05 | |
Why does getting care in America so often feel like navigating a maze? In this episode, I unpack the hidden architecture behind that confusion. U.S. healthcare is not one coherent system. It is a patchwork of rulebooks built over time through employer-sponsored insurance, Medicare, Medicaid, the ACA Marketplace, ERISA, and decades of political compromise. The result is a system where your job, age, income, disability status, or state can shape not just who pays, but which rules you live under. This episode explores why public programs increasingly flow through private managed care, why reform so often adds new layers instead of replacing old ones, and why complexity itself has become part of the business model of American healthcare. Timestamps
| |||
| How America Built the World’s Most Expensive Healthcare System | 25 mars 2026 | 00:43:01 | |
Why does the United States spend more on healthcare than any other country in the world, and still underperform on many basic health outcomes? In this episode, I unpack the machinery behind the high cost of American healthcare. From employer-sponsored insurance and tax policy to hospital consolidation, administrative complexity, and market power, this is a story about how the U.S. built a system that is extraordinarily expensive, highly fragmented, and remarkably hard to fix. This episode is not just about prices. It is about the architecture underneath them, the incentives, institutions, and historical decisions that made the system what it is today. Timestamps
| |||